OncoMatch/Clinical Trials/NCT07744256
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Is NCT07744256 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including EB-DART-NK01 and Lymphodepleting chemotherapy for small cell lung cancer (sclc).
Treatment: EB-DART-NK01 · Lymphodepleting chemotherapy — This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
Metastatic disease required
metastatic, extensive-stage, or unresectable, and relapsed or refractory after at least 1 prior systemic regimen
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy
relapsed or refractory after at least 1 prior systemic regimen (must include a platinum-based regimen unless contraindicated)
Must have received: platinum-based chemotherapy
must include a platinum-based regimen unless contraindicated
Cannot have received: therapy directed against the investigational target antigens
Exception: if it would confound safety/efficacy assessment
any prior therapy directed against the investigational target antigens if it would confound safety/efficacy assessment
Lab requirements
Blood counts
ANC ≥ 1.0 x10^9/L, platelets ≥ 75 x10^9/L
Kidney function
creatinine clearance ≥ 50 mL/min
Liver function
AST/ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN
Cardiac function
LVEF ≥ 45%
Adequate organ function (hematologic, renal, hepatic, and cardiac) as defined in the protocol (examples: ANC ≥ 1.0 x10^9/L, platelets ≥ 75 x10^9/L, creatinine clearance ≥ 50 mL/min, AST/ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07744256 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior therapy directed against the investigational target antigens disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages